# Progress Note 03 — Initial Preventive Physical Examination

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Frederick Cook (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EX006-SYN
- Date: 2026-08-04
- Fictional facility: St. Posthumous Health Center
- Fictional author: Harriet Okafor-Brandt, MD
- Calendar frame: modern shifted

- Visit type: Initial Preventive Physical Examination
- Services: HCPCS G0402 (initial preventive physical examination, within the first twelve months of Medicare Part B) with CPT 99497 (advance care planning), both on the same day; the screening ECG was done at the first visit

## Chief complaint

Welcome to Medicare preventive examination. **S**

## History of present illness

Mr. Cook is a 65-year-old man, released from prison on parole five months ago, with stage 2 hypertension and an asymptomatic stenosis of the right internal carotid artery, who comes for his Welcome to Medicare preventive examination now that his Medicare Part B has begun. Two weeks ago he started hydrochlorothiazide 25 mg, amlodipine 5 mg, atorvastatin 40 mg and aspirin 81 mg daily; he takes them from a weekly pill box and has missed no doses. He urinates more in the mornings, and has no dizziness, ankle swelling or muscle aches. His home readings this week average 142/86. He walks for an hour most days and is writing every morning. He has had no weakness, numbness, speech trouble or loss of vision. The screening tests from his first visit were reviewed with him: hepatitis C antibody nonreactive, the interferon-gamma release assay for tuberculosis negative, the HIV test nonreactive, and the hepatitis B panel negative for infection and for immunity. No vaccination records have come from the prison. **S**

| Element | Detail |
|---|---|
| Visit | Initial preventive physical examination, age 65 |
| New medicines | Hydrochlorothiazide, amlodipine, atorvastatin and aspirin for two weeks; no missed doses |
| Home blood pressure | Average 142/86 this week |
| Stroke symptoms | None |
| Screening results | Hepatitis C, tuberculosis and HIV negative; hepatitis B not immune |
| Mood | PHQ-2 1 |

## Health risk assessment

Completed by the patient on paper in the waiting room and reviewed with him face to face by Dr. Okafor-Brandt. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Fair; better since the room is settled |
| Psychosocial | Few friends nearby; reports to a parole officer monthly; feels ashamed when recognized |
| Tobacco | Never |
| Alcohol | None |
| Physical activity | Walks about an hour most days |
| Nutrition | Cooks simply on a hot plate; trying to eat less salt and more vegetables |
| Sleep | Six to seven hours |
| Oral health | No dental care for years; two loose back teeth, no pain |
| Safety | Smoke alarm in the rooming house; no firearms |
| Falls | No falls in the past year; steady on stairs |
| Activities of daily living | Independent in all, including medicines and money |
| Hearing and vision | Reading glasses; hearing normal by his report |
| Cognition | No concerns by his report |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever, night sweats, or weight loss |
| Eyes | Negative | No transient loss of vision |
| Ears, nose, mouth, and throat | Positive | Two loose back teeth without pain; hearing normal |
| Cardiovascular | Negative | No chest pain, palpitations, or ankle swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | No change in bowel habit, bleeding, or indigestion on aspirin |
| Genitourinary | Positive | More frequent urination in the mornings since the diuretic; normal stream |
| Musculoskeletal | Negative | No muscle aches on atorvastatin; no joint pain |
| Integumentary | Negative | No changing moles |
| Neurological | Negative | No weakness, numbness, speech trouble, or dizziness |
| Psychiatric | Negative | Mood fair; PHQ-2 score 1 |

11 systems reviewed. **S**

## Current medications

- Hydrochlorothiazide 25 mg tablet, one tablet by mouth each morning **S**
- Amlodipine 5 mg tablet, one tablet by mouth daily **S**
- Atorvastatin 40 mg tablet, one tablet by mouth daily **S**
- Aspirin 81 mg delayed-release tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 144/86 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 75.6 kg; BMI 24.7 kg/m². All vital signs are synthetic.

PHQ-2: 1. All results are synthetic.

## Immunizations given today

- Pneumococcal conjugate vaccine (PCV20) **S**
- Recombinant zoster vaccine, dose 1 of 2 **S**
- Tdap vaccine **S**
- Hepatitis B vaccine, CpG-adjuvanted (two-dose series), dose 1 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Well; weight 75.6 kg, BMI 24.7; blood pressure 144/86, pulse 70 |
| Eyes | Visual acuity with his glasses 20/30 in each eye |
| Ears | Whispered voice heard in both ears |
| Mouth | Two mobile lower molars with gum recession; no mass |
| Neck | Soft right carotid bruit, unchanged; no thyroid enlargement |
| Cardiovascular | Regular rhythm; no murmur; no ankle edema |
| Respiratory | Clear to auscultation bilaterally |
| Abdomen | Soft and non-tender; no pulsatile mass |
| Neurological | Gait steady; timed up-and-go 9 seconds; Mini-Cog 5 of 5 |
| Psychiatric | Courteous, engaged, and well spoken |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Initial preventive physical examination completed**. Health risk assessment reviewed and the prevention plan made. Pneumococcal conjugate, first recombinant zoster, Tdap and first hepatitis B vaccine doses given; colorectal cancer screening ordered; prostate cancer screening discussed and declined; vision, hearing, falls and cognition screened without concern. **S**
   - Second hepatitis B vaccine dose in about eight weeks, at the twelve-week visit.
   - Second zoster vaccine dose in two to six months.
   - Community dental clinic referral for the loose teeth.
   - Annual wellness visit in one year.
2. **Stage 2 hypertension** (I10). Improving two weeks after starting two drugs: office 144/86, home average 142/86; target below 130/80. Tolerating the medicines. **S**
   - Continue hydrochlorothiazide 25 mg and amlodipine 5 mg; electrolytes and creatinine at the six-week visit, as planned.
3. **Re-entry after incarceration** (Z65.2). Room secured by the week; benefits applications in progress with the social worker. **S**
   - Continue with the social worker on a longer lease and benefits.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Blood pressure | Completed today | 144/86 mmHg; treated hypertension |
| Depression screening | Completed today | PHQ-2 score 1; PHQ-9 7 at intake |
| Tobacco use | Completed today | Never used tobacco |
| Unhealthy alcohol use | Completed today | No alcohol |
| Colorectal cancer screening | Ordered | Never screened; he chose a yearly fecal immunochemical test; kit given |
| Prostate cancer screening | Declined | Shared decision about PSA screening at 55 to 69; after hearing the benefits and harms he chose not to be screened |
| Abdominal aortic aneurysm screening | Not indicated | Never smoked and no family history recorded |
| Lung cancer screening | Not indicated | Never smoked |
| Cholesterol and cardiovascular risk | Up to date | LDL 148 mg/dL at intake; on atorvastatin 40 mg for carotid atherosclerosis |
| Diabetes | Up to date | HbA1c 5.5% and fasting glucose 94 mg/dL at intake |
| Hepatitis C screening | Up to date | Antibody nonreactive at intake (signal-to-cutoff 0.08); repeat only with new risk |
| Latent tuberculosis screening | Up to date | Interferon-gamma release assay negative at intake; no cough, fever or weight loss |
| HIV screening | Up to date | Nonreactive at intake |
| Hepatitis B screening and vaccination | Completed today | Panel at intake negative for infection and immunity; CpG-adjuvanted hepatitis B vaccine dose 1 of 2 today, recommended at 60 or older with a risk factor such as incarceration |
| Pneumococcal vaccine | Completed today | PCV20 today; no further dose needed |
| Zoster vaccine | Completed today | Recombinant zoster vaccine dose 1 of 2 today |
| Tetanus, diphtheria, and pertussis | Completed today | Tdap today; no records of earlier doses |
| Influenza vaccine | Due | High-dose or adjuvanted vaccine in the autumn |
| COVID-19 vaccine | Declined | Current vaccine offered for adults 65 or older; he declined for now and will reconsider in the autumn |
| Vision | Completed today | 20/30 in each eye with glasses; optometry for new glasses |
| Hearing | Completed today | Whispered voice test normal |
| Falls risk | Completed today | No falls; timed up-and-go 9 seconds |
| Cognitive screening | Completed today | Mini-Cog 5 of 5; no concerns |
| Oral health | Referred | Community dental clinic for two loose molars; not covered by Medicare |

## Advance care planning

Voluntary advance care planning discussion of about 20 minutes, with his consent. He named a health care agent, a friend he trusts, and a health care proxy form was completed; the agent is recorded in the chart and is not named here. He would want full treatment for a stroke or heart attack, including clot-dissolving treatment and rehabilitation, and he would not want to be kept alive by machines if he could no longer think or write. The plan will be revisited at his annual wellness visit or after any serious illness. **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (Jones DW, et al. Hypertension 2025;82:e212-e316) (2025), American Heart Association; American College of Cardiology
- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Six-week review in two weeks, with electrolytes and creatinine. **S**
- Next scheduled visit 2026-08-18: six-week review: blood pressure, electrolytes and kidney function on hydrochlorothiazide and amlodipine; statin and aspirin tolerance. **S**
